<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38765011</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target.</ArticleTitle><Pagination><StartPage>1264702</StartPage><MedlinePgn>1264702</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1264702</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1264702</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Recently, we reported that post COVID-19 condition patients also have Transient Receptor Potential Melastatin 3 (TRPM3) ion channel dysfunction, a potential biomarker reported in natural killer (NK) cells from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) patients. As there is no universal treatment for post COVID-19 condition, knowledge of ME/CFS may provide advances to investigate therapeutic targets. Naltrexone hydrochloride (NTX) has been demonstrated to be beneficial as a pharmacological intervention for ME/CFS patients and experimental investigations have shown NTX restored TRPM3 function in NK cells. This research aimed to: i) validate impaired TRPM3 ion channel function in post COVID-19 condition patients compared with ME/CFS; and ii) investigate NTX effects on TRPM3 ion channel activity in post COVID-19 condition patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Whole-cell patch-clamp was performed to characterize TRPM3 ion channel activity in freshly isolated NK cells of post COVID-19 condition (<i>N</i> = 9; 40.56 &#xb1; 11.26 years), ME/CFS (<i>N</i> = 9; 39.33 &#xb1; 9.80 years) and healthy controls (HC) (<i>N</i> = 9; 45.22 &#xb1; 9.67 years). NTX effects were assessed on post COVID-19 condition (<i>N</i> = 9; 40.56 &#xb1; 11.26 years) and HC (<i>N</i> = 7; 45.43 &#xb1; 10.50 years) where NK cells were incubated for 24 hours in two protocols: treated with 200 &#xb5;M NTX, or non-treated; TRPM3 channel function was assessed with patch-clamp protocol.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">This investigation confirmed impaired TRPM3 ion channel function in NK cells from post COVID-19 condition and ME/CFS patients. Importantly, PregS-induced TRPM3 currents were significantly restored in NTX-treated NK cells from post COVID-19 condition compared with HC. Furthermore, the sensitivity of NK cells to ononetin was not significantly different between post COVID-19 condition and HC after treatment with NTX.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Our findings provide further evidence identifying similarities of TRPM3 ion channel dysfunction between ME/CFS and post COVID-19 condition patients. This study also reports, for the first time, TRPM3 ion channel activity was restored in NK cells isolated from post COVID-19 condition patients after <i>in vitro</i> treatment with NTX. The TRPM3 restoration consequently may re-establish TRPM3-dependent calcium (Ca<sup>2+</sup>) influx. This investigation proposes NTX as a potential therapeutic intervention and TRPM3 as a treatment biomarker for post COVID-19 condition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Sasso, Muraki, Eaton-Fitch, Smith, Jeremijenko, Griffin and Marshall-Gradisnik.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sasso</LastName><ForeName>Etianne Martini</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consortium Health International for Myalgic Encephalomyelitis, National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muraki</LastName><ForeName>Katsuhiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Consortium Health International for Myalgic Encephalomyelitis, National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Cellular Pharmacology, School of Pharmacy, Aichi-Gakuin University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eaton-Fitch</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consortium Health International for Myalgic Encephalomyelitis, National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Consortium Health International for Myalgic Encephalomyelitis, National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medicine, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeremijenko</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consortium Health International for Myalgic Encephalomyelitis, National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine and Infectious Diseases, Mater Hospital and Mater Medical Research Institute, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall-Gradisnik</LastName><ForeName>Sonya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consortium Health International for Myalgic Encephalomyelitis, National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5S6W795CQM</RegistryNumber><NameOfSubstance UI="D009271">Naltrexone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050053">TRPM Cation Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475667">TRPM3 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="N">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009271" MajorTopicYN="N">Naltrexone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050053" MajorTopicYN="Y">TRPM Cation Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">calcium</Keyword><Keyword MajorTopicYN="N">long Covid</Keyword><Keyword MajorTopicYN="N">myalgic encephalomyelitis/chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">naltrexone hydrochloride</Keyword><Keyword MajorTopicYN="N">post COVID-19 condition</Keyword><Keyword MajorTopicYN="N">transient receptor potential melastatin 3</Keyword><Keyword MajorTopicYN="N">whole-cell patch-clamp electrophysiology</Keyword></KeywordList><CoiStatement>EMS, NE-F and SM-G declare an Australian provisional patent application 2022902253 entitled &#x201c;Methods for detecting post COVID-19 condition&#x201d; relates to the use of Transient Receptor Potential ion channels dysfunction in identifying, screening, diagnosing, or managing/treating people with post COVID-19 condition. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>20</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38765011</ArticleId><ArticleId IdType="pmc">PMC11099221</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1264702</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lledo GM, Sellares J, Brotons C, Sans M, Anton JD, Blanco J, et al. . Post-acute COVID-19 syndrome: a new tsunami requiring a universal case definition. Clin Microbiol Infect. (2021) 28(3):315&#x2013;8. doi:&#xa0;10.1016/j.cmi.2021.11.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.015</ArticleId><ArticleId IdType="pmc">PMC8610558</ArticleId><ArticleId IdType="pubmed">34826619</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization . A clinical case definition of post COVID-19 condition by a Delphi consensus. (2021). Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. . Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. (2021) 4:e210830. doi:&#xa0;10.1001/jamanetworkopen.2021.0830</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PloS Med. (2021) 18:e1003773. doi:&#xa0;10.1371/journal.pmed.1003773</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization . WHO Coronavirus (COVID-19) Dashboard. World Health Organization;  (2021). Available at: https://covid19.who.int/.</Citation></Reference><Reference><Citation>Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-A systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas). (2021) 57. doi:&#xa0;10.3390/medicina57050418</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050418</ArticleId><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>PHOSP-COVID Collaborative Group . Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. (2022) 10(8):761&#x2013;75. doi:&#xa0;10.1016/S2213-2600(22)00127-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Saydah SH, Brooks JT, Jackson BR. Surveillance for post-COVID conditions is necessary: addressing the challenges with multiple approaches. J Gen Intern Med. (2022) 37:1786&#x2013;8. doi:&#xa0;10.1007/s11606-022-07446-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07446-z</ArticleId><ArticleId IdType="pmc">PMC8853042</ArticleId><ArticleId IdType="pubmed">35167066</ArticleId></ArticleIdList></Reference><Reference><Citation>Brightling CE, Evans RA. Long COVID: which symptoms can be attributed to SARS-CoV-2 infection? Lancet. (2022) 400:411&#x2013;3. doi:&#xa0;10.1016/S0140-6736(22)01385-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01385-X</ArticleId><ArticleId IdType="pmc">PMC9352303</ArticleId><ArticleId IdType="pubmed">35933996</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L, Tosto-Mancuso J, Wood J, Cortes M, Kontorovich A, McCarthy D, et al. . Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life and participation. Am J Phys Med Rehabil. (2022) 101(1):48&#x2013;52. doi:&#xa0;10.1097/PHM.0000000000001910</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHM.0000000000001910</ArticleId><ArticleId IdType="pmc">PMC8667685</ArticleId><ArticleId IdType="pubmed">34686631</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health. (2022) 24:100485. doi:&#xa0;10.1016/j.bbih.2022.100485</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100485</ArticleId><ArticleId IdType="pmc">PMC9250701</ArticleId><ArticleId IdType="pubmed">35814187</ArticleId></ArticleIdList></Reference><Reference><Citation>de Miranda DAP, Gomes SVC, Filgueiras PS, Corsini CA, Almeida NBF, Silva RA, et al. . Long COVID-19 syndrome: a 14-months longitudinal study during the two first epidemic peaks in Southeast Brazil. Trans R Soc Trop Med Hyg. (2022) 116(11):1007&#x2013;14. doi:&#xa0;10.1093/trstmh/trac030</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/trstmh/trac030</ArticleId><ArticleId IdType="pubmed">35514142</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung TJ, Neumann C, Bahmer T, Chaplinskaya-Sobol I, Endres M, Geritz J, et al. . Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. EClinicalMedicine. (2022) 53:101651. doi:&#xa0;10.1016/j.eclinm.2022.101651</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101651</ArticleId><ArticleId IdType="pmc">PMC9482331</ArticleId><ArticleId IdType="pubmed">36133318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. . More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv. (2021) 11(1):16144. doi:&#xa0;10.21203/rs.3.rs-266574/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-266574/v1</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani E, Mariotto S, Gabbiani D, Dorelli G, Bozzetti S, Federico A, et al. . Chronic fatigue syndrome: an emerging sequela in COVID-19 survivors? J Neurovirol. (2021) 27:631&#x2013;7. doi:&#xa0;10.1007/s13365-021-01002-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-01002-x</ArticleId><ArticleId IdType="pmc">PMC8328351</ArticleId><ArticleId IdType="pubmed">34341960</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med (Lausanne). (2020) 7:606824. doi:&#xa0;10.3389/fmed.2020.606824</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.606824</ArticleId><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Post-acute COVID-19 syndrome. Nat Med. (2021) 27:601&#x2013;15. doi:&#xa0;10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG . Persistent symptoms in patients after acute COVID-19. JAMA. (2020) 324:603&#x2013;5. doi:&#xa0;10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. . Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PloS One. (2020) 15:e0240784. doi:&#xa0;10.1371/journal.pone.0240784</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240784</ArticleId><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Poenaru S, Abdallah SJ, Corrales-Medina V, Cowan J. COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review. Ther Adv Infect Dis. (2021) 8:20499361211009385. doi:&#xa0;10.1177/20499361211009385</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20499361211009385</ArticleId><ArticleId IdType="pmc">PMC8060761</ArticleId><ArticleId IdType="pubmed">33959278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukocheva OA, Maksoud R, Beeraka NM, Madhunapantula SV, Sinelnikov M, Nikolenko VN, et al. . Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome. J Advanced Res. (2021) 40:179&#x2013;96. doi:&#xa0;10.1016/j.jare.2021.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jare.2021.11.013</ArticleId><ArticleId IdType="pmc">PMC8619886</ArticleId><ArticleId IdType="pubmed">36100326</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re&#x2019;em Y, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. (2021) 38:101019. doi:&#xa0;10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Salisbury H. Helen Salisbury: When will we be well again? BMJ. (2020) 369:m2490. doi:&#xa0;10.1136/bmj.m2490</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2490</ArticleId><ArticleId IdType="pubmed">32576550</ArticleId></ArticleIdList></Reference><Reference><Citation>Balinas C, Eaton-Fitch N, Maksoud R, Staines D, Marshall-Gradisnik S. Impact of life stressors on myalgic encephalomyelitis/chronic fatigue syndrome symptoms: an Australian longitudinal study. Int J Environ Res Public Health. (2021) 18:10614. doi:&#xa0;10.3390/ijerph182010614</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph182010614</ArticleId><ArticleId IdType="pmc">PMC8535742</ArticleId><ArticleId IdType="pubmed">34682360</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. . Myalgic encephalomyelitis: international consensus criteria. J Intern Med. (2011) 270:327&#x2013;38. doi:&#xa0;10.1111/j.1365-2796.2011.02428.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2011.02428.x</ArticleId><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasa S, Nora-Krukle Z, Henning N, Eliassen E, Shikova E, Harrer T, et al. . Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med. (2018) 16:268. doi:&#xa0;10.1186/s12967-018-1644-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1644-y</ArticleId><ArticleId IdType="pmc">PMC6167797</ArticleId><ArticleId IdType="pubmed">30285773</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton-Fitch N, Johnston SC, Zalewski P, Staines D, Marshall-Gradisnik S. Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study. Qual Life Res. (2020) 29:1521&#x2013;31. doi:&#xa0;10.1007/s11136-019-02411-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-019-02411-6</ArticleId><ArticleId IdType="pmc">PMC7253372</ArticleId><ArticleId IdType="pubmed">31970624</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall-Gradisnik S, Eaton-Fitch N. Understanding myalgic encephalomyelitis. Science. (2022) 377:1150&#x2013;1. doi:&#xa0;10.1126/science.abo1261</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abo1261</ArticleId><ArticleId IdType="pubmed">36074854</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall-Gradisnik S, Huth T, Chacko A, Johnston S, Smith P, Staines D. Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome. Appl Clin Genet. (2016) 9:39&#x2013;47. doi:&#xa0;10.2147/TACG</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TACG</ArticleId><ArticleId IdType="pmc">PMC4821384</ArticleId><ArticleId IdType="pubmed">27099524</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T, Johnston S, Clarke L, Smith P, Staines D, Marshall-Gradisnik S. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. Clin Exp Immunol. (2017) 187:284&#x2013;93. doi:&#xa0;10.1111/cei.12882</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12882</ArticleId><ArticleId IdType="pmc">PMC5217865</ArticleId><ArticleId IdType="pubmed">27727448</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H, Muraki K, Eaton N, Balinas C, Staines D, Marshall-Gradisnik S. Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. Mol Med. (2018) 24:44. doi:&#xa0;10.1186/s10020-018-0046-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-018-0046-1</ArticleId><ArticleId IdType="pmc">PMC6092868</ArticleId><ArticleId IdType="pubmed">30134818</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T, Staines D, Nilius B, Smith P, Marshall-Gradisnik S. Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients. Biol Res. (2016) 49:27. doi:&#xa0;10.1186/s40659-016-0087-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40659-016-0087-2</ArticleId><ArticleId IdType="pmc">PMC4888729</ArticleId><ArticleId IdType="pubmed">27245705</ArticleId></ArticleIdList></Reference><Reference><Citation>Chacko A, Staines DR, Johnston SC, Marshall-Gradisnik SM. Dysregulation of protein kinase gene expression in NK cells from chronic fatigue syndrome/myalgic encephalomyelitis patients. Gene Regul Syst Bio. (2016) 10:85&#x2013;93. doi:&#xa0;10.4137/GRSB.S40036</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/GRSB.S40036</ArticleId><ArticleId IdType="pmc">PMC5003121</ArticleId><ArticleId IdType="pubmed">27594784</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton-Fitch N, Du Preez S, Cabanas H, Muraki K, Staines D, Marshall-Gradisnik S. Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients. J Transl Med. (2022) 20:94. doi:&#xa0;10.1186/s12967-022-03297-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03297-8</ArticleId><ArticleId IdType="pmc">PMC8848670</ArticleId><ArticleId IdType="pubmed">35172836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev. (2009) 8:287&#x2013;91. doi:&#xa0;10.1016/j.autrev.2008.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2008.08.003</ArticleId><ArticleId IdType="pubmed">18801465</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermeier F, Lacerda EM, Scheibenbogen C, Sepulveda N. Editorial: current insights into complex post-infection fatigue syndromes with unknown aetiology: the case of myalgic encephalomyelitis/chronic fatigue syndrome and beyond. Front Med (Lausanne). (2022) 9:862953. doi:&#xa0;10.3389/fmed.2022.862953</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.862953</ArticleId><ArticleId IdType="pmc">PMC8907997</ArticleId><ArticleId IdType="pubmed">35280890</ArticleId></ArticleIdList></Reference><Reference><Citation>Montell C, Birnbaumer L, Flockerzi V. The TRP channels, a remarkably functional family. Cell. (2002) 108:595&#x2013;8. doi:&#xa0;10.1016/S0092-8674(02)00670-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(02)00670-0</ArticleId><ArticleId IdType="pubmed">11893331</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilius B, Owsianik G. The transient receptor potential family of ion channels. Genome Biol. (2011) 12:218. doi:&#xa0;10.1186/gb-2011-12-3-218</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2011-12-3-218</ArticleId><ArticleId IdType="pmc">PMC3129667</ArticleId><ArticleId IdType="pubmed">21401968</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H. TRP channel classification. Adv Exp Med Biol. (2017) 976:1&#x2013;8. doi:&#xa0;10.1007/978-94-024-1088-4_1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-94-024-1088-4_1</ArticleId><ArticleId IdType="pubmed">28508308</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiel G, Muller I, Rossler OG. Signal transduction via TRPM3 channels in pancreatic beta-cells. J Mol Endocrinol. (2013) 50:R75&#x2013;83. doi:&#xa0;10.1530/JME-12-0237</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JME-12-0237</ArticleId><ArticleId IdType="pubmed">23511953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Chen J, Sun L, Wu S, Gray KR, Rich A, et al. . Expression and characterization of human transient receptor potential melastatin 3 (hTRPM3). J Biol Chem. (2003) 278:20890&#x2013;7. doi:&#xa0;10.1074/jbc.M211232200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M211232200</ArticleId><ArticleId IdType="pubmed">12672827</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz EC, Qu B, Hoth M. Calcium, cancer and killing: the role of calcium in killing cancer cells by cytotoxic T lymphocytes and natural killer cells. Biochim Biophys Acta. (2013) 1833:1603&#x2013;11. doi:&#xa0;10.1016/j.bbamcr.2012.11.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2012.11.016</ArticleId><ArticleId IdType="pubmed">23220009</ArticleId></ArticleIdList></Reference><Reference><Citation>Clapham DE. Calcium signaling. Cell. (2007) 131:1047&#x2013;58. doi:&#xa0;10.1016/j.cell.2007.11.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.11.028</ArticleId><ArticleId IdType="pubmed">18083096</ArticleId></ArticleIdList></Reference><Reference><Citation>Balinas C, Cabanas H, Staines D, Marshall-Gradisnik S. Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients. J Transl Med. (2019) 17:401. doi:&#xa0;10.1186/s12967-019-02155-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-019-02155-4</ArticleId><ArticleId IdType="pmc">PMC6891975</ArticleId><ArticleId IdType="pubmed">31796045</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffal SM, Abbas MA. TRP channels in COVID-19 disease: Potential targets for prevention and treatment. Chemico-Biological Interact. (2021) 345:109567. doi:&#xa0;10.1016/j.cbi.2021.109567</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2021.109567</ArticleId><ArticleId IdType="pmc">PMC8217345</ArticleId><ArticleId IdType="pubmed">34166652</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlansky S, Sallinger M, Grabmayr H, Humer C, Bernhard A, Fahrner M, et al. . Calcium signals during SARS-CoV-2 infection: Assessing the potential of emerging therapies. Cells. (2022) 11:253. doi:&#xa0;10.3390/cells11020253</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11020253</ArticleId><ArticleId IdType="pmc">PMC8773957</ArticleId><ArticleId IdType="pubmed">35053369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar PS, Radhakrishnan A, Mukherjee T, Khamaru S, Chattopadhyay S, Chattopadhyay S. Understanding the role of Ca2+ via transient receptor potential (TRP) channel in viral infection: Implications in developing future antiviral strategies. Virus Res. (2023) 323:198992. doi:&#xa0;10.1016/j.virusres.2022.198992</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2022.198992</ArticleId><ArticleId IdType="pmc">PMC10194134</ArticleId><ArticleId IdType="pubmed">36309316</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H, Muraki K, Balinas C, Eaton-Fitch N, Staines D, Marshall-Gradisnik S. Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. Mol Med. (2019) 25:14. doi:&#xa0;10.1186/s10020-019-0083-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-019-0083-4</ArticleId><ArticleId IdType="pmc">PMC6480905</ArticleId><ArticleId IdType="pubmed">31014226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H, Muraki K, Staines D, Marshall-Gradisnik S. Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients. Front Immunol. (2019) 10:2545. doi:&#xa0;10.3389/fimmu.2019.02545</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02545</ArticleId><ArticleId IdType="pmc">PMC6834647</ArticleId><ArticleId IdType="pubmed">31736966</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, et al. . Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med. (2011) 9:81. doi:&#xa0;10.1186/1479-5876-9-81</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-9-81</ArticleId><ArticleId IdType="pmc">PMC3120691</ArticleId><ArticleId IdType="pubmed">21619669</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal AS, Bradley AS, Bishop KN, Kiani-Alikhan S, Ford B. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun. (2012) 26:24&#x2013;31. doi:&#xa0;10.1016/j.bbi.2011.06.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2011.06.016</ArticleId><ArticleId IdType="pubmed">21756995</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenu EW, Huth TK, Hardcastle SL, Fuller K, Kaur M, Johnston S, et al. . Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immunol. (2014) 26:233&#x2013;42. doi:&#xa0;10.1093/intimm/dxt068</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxt068</ArticleId><ArticleId IdType="pubmed">24343819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasso EM, Muraki K, Eaton-Fitch N, Smith P, Lesslar OL, Deed G, et al. . Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients. Mol Med. (2022) 28:98. doi:&#xa0;10.1186/s10020-022-00528-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-022-00528-y</ArticleId><ArticleId IdType="pmc">PMC9388968</ArticleId><ArticleId IdType="pubmed">35986236</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. (2022) 28:911&#x2013;23. doi:&#xa0;10.1038/s41591-022-01810-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu N, Meng Y, Handley MK, Wang C, Shan F. Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy. Int Immunopharmacol. (2021) 96:107714. doi:&#xa0;10.1016/j.intimp.2021.107714</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107714</ArticleId><ArticleId IdType="pubmed">33989971</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H, Muraki K, Eaton-Fitch N, Staines DR, Marshall-Gradisnik S. Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome: role of transient receptor potential melastatin 3 ion channels in pathophysiology and treatment. Front Immunol. (2021) 12:687806. doi:&#xa0;10.3389/fimmu.2021.687806</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.687806</ArticleId><ArticleId IdType="pmc">PMC8313851</ArticleId><ArticleId IdType="pubmed">34326841</ArticleId></ArticleIdList></Reference><Reference><Citation>Ninkovic J, Roy S. Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids. (2013) 45:9&#x2013;24. doi:&#xa0;10.1007/s00726-011-1163-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-011-1163-0</ArticleId><ArticleId IdType="pmc">PMC3912755</ArticleId><ArticleId IdType="pubmed">22170499</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. (1994) 121:953&#x2013;9. doi:&#xa0;10.7326/0003-4819-121-12-199412150-00009</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-121-12-199412150-00009</ArticleId><ArticleId IdType="pubmed">7978722</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner A, et al. . Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndrome. (2003) 11:7&#x2013;115. doi:&#xa0;10.1300/J092v11n01_02</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J092v11n01_02</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Institute of Health and Welfare . SF-36 interim norms for Australian data. (1996) Canberra, Australia.</Citation></Reference><Reference><Citation>
&#xdc;st&#xfc;n T, Kostanjsek N, Chatterji S, Rehm J. Measuring health and disability: Manual for WHO disability assessment schedule - WHODAS 2.0.2010 (2022). Available online at: https://apps.who.int/iris/handle/10665/43974.</Citation></Reference><Reference><Citation>Andrews G, Kemp A, Sunderland M, Von Korff M, Ustun TB. Normative data for the 12 item WHO Disability Assessment Schedule 2.0. PloS One. (2009) 17:e8343. doi:&#xa0;10.1371/journal.pone.0008343</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008343</ArticleId><ArticleId IdType="pmc">PMC2791224</ArticleId><ArticleId IdType="pubmed">20020047</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz NM, Leff AR. Highly purified selective isolation of eosinophils from human peripheral blood by negative immunomagnetic selection. Nat Protoc. (2006) 1:2613&#x2013;20. doi:&#xa0;10.1038/nprot.2006.340</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.340</ArticleId><ArticleId IdType="pubmed">17406516</ArticleId></ArticleIdList></Reference><Reference><Citation>Straub I, Mohr F, Stab J, Konrad M, Philipp SE, Oberwinkler J, et al. . Citrus fruit and fabacea secondary metabolites potently and selectively block TRPM3. Br J Pharmacol. (2013) 168:1835&#x2013;50. doi:&#xa0;10.1111/bph.12076</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12076</ArticleId><ArticleId IdType="pmc">PMC3623054</ArticleId><ArticleId IdType="pubmed">23190005</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiel G, Rubil S, Lesch A, Guethlein LA, Rossler OG. Transient receptor potential TRPM3 channels: Pharmacology, signaling, and biological functions. Pharmacol Res. (2017) 124:92&#x2013;9. doi:&#xa0;10.1016/j.phrs.2017.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2017.07.014</ArticleId><ArticleId IdType="pubmed">28720517</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, MacKinnon R. Structural and functional analyses of a GPCR-inhibited ion channel TRPM3. Neuron. (2023) 111:81&#x2013;91.e7. doi:&#xa0;10.1016/j.neuron.2022.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.10.002</ArticleId><ArticleId IdType="pubmed">36283409</ArticleId></ArticleIdList></Reference><Reference><Citation>Badheka D, Yudin Y, Borbiro I, Hartle CM, Yazici A, Mirshahi T, et al. . Inhibition of Transient Receptor Potential Melastatin 3 ion channels by G-protein betagamma subunits. Elife. (2017) 6:e26147. doi:&#xa0;10.7554/eLife.26147</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.26147</ArticleId><ArticleId IdType="pmc">PMC5593506</ArticleId><ArticleId IdType="pubmed">28829742</ArticleId></ArticleIdList></Reference><Reference><Citation>Dembla S, Behrendt M, Mohr F, Goecke C, Sondermann J, Schneider FM, et al. . Anti-nociceptive action of peripheral mu-opioid receptors by G-beta-gamma protein-mediated inhibition of TRPM3 channels. Elife. (2017) 6:e26280. doi:&#xa0;10.7554/eLife.26280</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.26280</ArticleId><ArticleId IdType="pmc">PMC5593507</ArticleId><ArticleId IdType="pubmed">28826482</ArticleId></ArticleIdList></Reference><Reference><Citation>Quallo T, Alkhatib O, Gentry C, Andersson DA, Bevan S. G protein betagamma subunits inhibit TRPM3 ion channels in sensory neurons. Elife. (2017) 6:e26138. doi:&#xa0;10.7554/eLife.26138</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.26138</ArticleId><ArticleId IdType="pmc">PMC5593501</ArticleId><ArticleId IdType="pubmed">28826490</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrendt M, Gruss F, Enzeroth R, Dembla S, Zhao S, Crassous PA, et al. . The structural basis for an on-off switch controlling Gbetagamma-mediated inhibition of TRPM3 channels. Proc Natl Acad Sci U.S.A. (2020) 117:29090&#x2013;100. doi:&#xa0;10.1073/pnas.2001177117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2001177117</ArticleId><ArticleId IdType="pmc">PMC7682392</ArticleId><ArticleId IdType="pubmed">33122432</ArticleId></ArticleIdList></Reference><Reference><Citation>Toljan K, Vrooman B. Low-dose naltrexone (LDN)-review of therapeutic utilization. Med Sci (Basel). (2018) 6(4):82. doi:&#xa0;10.3390/medsci6040082</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medsci6040082</ArticleId><ArticleId IdType="pmc">PMC6313374</ArticleId><ArticleId IdType="pubmed">30248938</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton MJ, Chapman BP, Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. (2020) 13(1):e232502. doi:&#xa0;10.1136/bcr-2019-232502</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2019-232502</ArticleId><ArticleId IdType="pmc">PMC6954765</ArticleId><ArticleId IdType="pubmed">31911410</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton M, Hodkinson A, Boda S, Mould A, Panagioti M, Rhodes S, et al. . Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis. BMC Med. (2019) 17:10. doi:&#xa0;10.1186/s12916-018-1242-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-018-1242-0</ArticleId><ArticleId IdType="pmc">PMC6332608</ArticleId><ArticleId IdType="pubmed">30642329</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo O, Pesonen P, Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue: Biomedicine Health Behav. (2019) 7:207&#x2013;2017. doi:&#xa0;10.1080/21641846.2019.1692770</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2019.1692770</ArticleId></ArticleIdList></Reference><Reference><Citation>Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. (2013) 65:529&#x2013;38. doi:&#xa0;10.1002/art.37734</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37734</ArticleId><ArticleId IdType="pubmed">23359310</ArticleId></ArticleIdList></Reference><Reference><Citation>Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. (2010) 68:145&#x2013;50. doi:&#xa0;10.1002/ana.22006</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22006</ArticleId><ArticleId IdType="pubmed">20695007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. (2010) 16:964&#x2013;9. doi:&#xa0;10.1177/1352458510366857</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458510366857</ArticleId><ArticleId IdType="pubmed">20534644</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WM, Scott KA, Dennis JL, Kaminska E, Levett AJ, Dalgleish AG. Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy. Int J Oncol. (2016) 49:793&#x2013;802. doi:&#xa0;10.3892/ijo.2016.3567</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2016.3567</ArticleId><ArticleId IdType="pubmed">27279602</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, et al. . Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn&#x2019;s disease: a randomized placebo-controlled trial. Dig Dis Sci. (2011) 56:2088&#x2013;97. doi:&#xa0;10.1007/s10620-011-1653-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-011-1653-7</ArticleId><ArticleId IdType="pmc">PMC3381945</ArticleId><ArticleId IdType="pubmed">21380937</ArticleId></ArticleIdList></Reference><Reference><Citation>Seessle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. . Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis. (2021) 74(7):1191&#x2013;8. doi:&#xa0;10.1093/cid/ciab611</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. . Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. (2021) 325:2015&#x2013;6. doi:&#xa0;10.1001/jama.2021.5612</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.5612</ArticleId><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Zhao H, Tebbutt SJ. A glimpse into long COVID and symptoms. Lancet Respir Med. (2022) 10:e81. doi:&#xa0;10.1016/S2213-2600(22)00217-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00217-X</ArticleId><ArticleId IdType="pmc">PMC9187332</ArticleId><ArticleId IdType="pubmed">35697054</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>